
    
      Infants with cyanotic congenital heart disease will be randomly assigned to receive either a
      placebo or probiotic Bifidobacterium infantis. Comparisons will be made between the infants
      receiving the placebo and healthy infants without heart disease and between the infants
      receiving the placebo and those receiving the probiotic.
    
  